Savara (SVRA) Equity Average (2011 - 2026)
Savara (SVRA) reported Equity Average of $189.6 million for Q1 2026, up 18.75% year-over-year from $159.6 million in Q1 2025, and up 86.8% quarter-over-quarter from $101.5 million in Q4 2025.
Savara (SVRA) Equity Average (2011 - 2026) Analysis & Trends
Savara (SVRA) has 16 years of Equity Average data on file, last reported at $189.6 million in Q1 2026.
- Equity Average for Q1 2026 came in at $189.6 million, up 18.75% year-over-year; the trailing twelve-month figure through Mar 2026 was $189.6 million (up 18.75% YoY), and the FY2025 annual result was $187.3 million, up 118.83% from the prior year.
- Equity Average climbed to $189.6 million in Q1 2026 per SVRA's latest filing, from $101.5 million in the prior quarter.
- Over five years, Equity Average peaked at $189.6 million in Q1 2026 and troughed at $48.8 million in Q1 2023.
- A 5-year average of $114.0 million and a median of $117.1 million in 2023 frame the typical range for Equity Average.
- The sharpest annual moves came in 2023 and 2025: Equity Average plunged 65.25% in 2023, then soared 162.6% in 2025.
- A 5-year view of Equity Average shows it stood at $58.0 million in 2022, then gained by 26.2% to $73.1 million in 2023, then jumped by 153.5% to $185.4 million in 2024, then tumbled by 45.26% to $101.5 million in 2025, then soared by 86.8% to $189.6 million in 2026.
- Business Quant data shows SVRA's Equity Average at $189.6 million in Q1 2026, $101.5 million in Q4 2025, and $60.2 million in Q3 2025.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Equity Avg. (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - | 3.50 Bn |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - | 783.14 Mn |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - | 3.76 Mn |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn | 1.01 Bn |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - | - |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - | 21.35 Mn |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - | - |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn | 19.01 Bn |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - | 516.41 Mn |
| 10 | Savara | 1.39 Bn | 1.39 Bn | - | 189.59 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 189.59 Mn |
| Dec 31, 2025 | 101.49 Mn |
| Sep 30, 2025 | 60.16 Mn |
| Jun 30, 2025 | 134.17 Mn |
| Mar 31, 2025 | 159.65 Mn |
| Dec 31, 2024 | 185.40 Mn |
| Sep 30, 2024 | 150.54 Mn |
| Jun 30, 2024 | 111.80 Mn |
| Mar 31, 2024 | 60.80 Mn |
| Dec 31, 2023 | 73.14 Mn |
| Sep 30, 2023 | 117.13 Mn |
| Jun 30, 2023 | 92.99 Mn |
| Mar 31, 2023 | 48.83 Mn |
| Dec 31, 2022 | 57.95 Mn |
| Sep 30, 2022 | 121.78 Mn |
| Jun 30, 2022 | 131.76 Mn |
| Mar 31, 2022 | 140.49 Mn |
| Dec 31, 2021 | 149.86 Mn |
| Sep 30, 2021 | 160.31 Mn |
| Jun 30, 2021 | 170.25 Mn |